

## Lupin partners with Fuji to strengthen women's health portfolio in Vietnam and Philippines

14 June 2024 | News

For marketing Nextstellis, a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4)



India-headquartered pharma major Lupin has signed a license and supply agreement with OLIC (Thailand), a subsidiary of Japanese pharmaceutical company Fuji Pharma Co., for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and Philippines.

Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.

"We are delighted to collaborate with Fuji and OLIC to offer Nextstellis to our patients in Vietnam and the Philippines. This new addition to our Women's Health portfolio will strengthen our commitment to expand healthcare options worldwide," said Dr Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

Fuji focuses on the field of women's healthcare with a wide variety of new and generic drugs for women's specific diseases such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders.